Trial NCT04640168
Publication ACTT-4 - Wolfe CR, Lancet Respir Med (2022) (published paper)
Dates: 2020-12-01 to 2021-04-13
Funding: Public/non profit (Gilead Sciences provided remdesivir for use in this trial but did not provide any financial support. Eli Lilly provided baricitinib for use in this trial but did not provide any financial support. Employees of Gilead Sciences and Eli Lilly participated in discussions about protocol development and in weekly protocol team calls. Input from the manufacturer of baricitinib, Eli Lilly, Indianapolis, IN, USA, was considered by the investigators. The National Institute of Allergy and Infectious Diseases (NIAID) ultimately made all decisions regarding trial design and implementation. The trial was sponsored and primarily funded by the NIAID, National Institutes of Health. This trial has also been funded in part by the National Cancer Institute, US Department of Defense, Defense Health Program, the governments of Japan, Mexico, and Singapore, Seoul National University Hospital, and Seoul National University Bundang Hospital.)
Conflict of interest: No